Compare ORGN & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORGN | CMMB |
|---|---|---|
| Founded | 2008 | 2004 |
| Country | United States | Israel |
| Employees | 91 | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4M | 11.2M |
| IPO Year | N/A | 2023 |
| Metric | ORGN | CMMB |
|---|---|---|
| Price | $2.10 | $1.69 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 501.6K | 43.1K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | $503.74 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $42.50 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.10 | $0.87 |
| 52 Week High | $4.11 | $3.86 |
| Indicator | ORGN | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 56.60 | 51.22 |
| Support Level | $0.35 | $1.44 |
| Resistance Level | $4.11 | $1.86 |
| Average True Range (ATR) | 0.36 | 0.13 |
| MACD | -0.13 | 0.01 |
| Stochastic Oscillator | 8.75 | 61.90 |
Origin Materials Inc is a carbon-negative materials company. The platform turns the carbon found in biomass into useful materials, while eliminating the need for fossil resources and capturing carbon in the process. Its products include, PET circular caps and closures, Para-xylene, carbon black, Levulinic acid among others by using materials like food and beverage packaging, clothing, textiles, plastics, car parts, carpeting, tires, adhesives, soil amendments, and fuels.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.